When combined with immune checkpoint inhibitors (ICIs), particularly those targeting the PD-1/PD-L1 axis, they hold great promise for the treatment of various cancers, such as non-small cell lung carcinoma [41]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.